SAMHD1 and acute myeloid leukemia: AML blasts in sections of paraffinized bone-marrow specimens taken at primary diagnosis from a multi-centric cohort of adult AML patients, 55 of which received first-line DAC monotherapy and 48 of which received first-line AZA monotherapy (detailed patient characteristics are listed in Supplementary Data file 2), were retrospectively analyzed for SAMHD1 protein levels in blasts by immunohistochemical (IHC) staining and histopathological evaluation in a blinded manner.